Latest News for: bbo

Edit

Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants (Bridgebio Oncology Therapeutics Inc)

Public Technologies 10 Mar 2026
Identification of BBO-11818, a Potent and Selective Dual Inhibitor of KRAS ... Compared with our covalent KRASG12C inhibitor BBO-8520 (13), BBO-11818 can target a broader range of KRAS mutants ... BBO-8520 ... BBO-8520 KD (nmol/L) ... BBO-11818 KD (nmol/L).
  • 1
×